2022 Systemic lupus erythematosus remission in clinical practice. Message for Polish rheumatologists

Reumatologia. 2022;60(2):125-132. doi: 10.5114/reum.2022.115667. Epub 2022 May 18.

Abstract

Systemic lupus erythematosus (SLE) is a complicated multiorgan disease and can lead to organ damage and increased risk of morbidity and mortality. The strategy of management while avoiding complications, especially caused by chronic glucocorticoid therapy, improves outcomes. Different definitions of the treatment goal in different configurations of lupus activity indexes have appeared over the years. In 2021 the definition of remission and recommendations for its achievement were published and it become a way to implement a treat-to-target strategy. The main goal of treatment has become DORIS (definition of remission in SLE) remission and the alternative LLDAS (low lupus disease activity state). Prolonging remission with clinical and immunological lupus activity restrictions and minimizing or stopping steroid doses reduced flares and damage accrual. The analysis and neutralization of poor prognosis predictive factors in lupus could be the most beneficial for less morbidity and mortality and better quality of life.

Keywords: DORIS remission; Systemic Lupus Erythematosus Disease Activity Index; lupus low disease activity state; systemic lupus erythematosus.

Publication types

  • Review